SG11202102405YA - 1h-indazole carboxamides as receptor-interacting protein kinase 1 inhibitors (ripk1) - Google Patents

1h-indazole carboxamides as receptor-interacting protein kinase 1 inhibitors (ripk1)

Info

Publication number
SG11202102405YA
SG11202102405YA SG11202102405YA SG11202102405YA SG11202102405YA SG 11202102405Y A SG11202102405Y A SG 11202102405YA SG 11202102405Y A SG11202102405Y A SG 11202102405YA SG 11202102405Y A SG11202102405Y A SG 11202102405YA SG 11202102405Y A SG11202102405Y A SG 11202102405YA
Authority
SG
Singapore
Prior art keywords
alkyl
cycloalkyl
phenyl
methyl
heterocycle
Prior art date
Application number
SG11202102405YA
Other languages
English (en)
Inventor
Junqing Guo
Jie Chen
Carolyn Diane Dzierba
Amy C Hart
Guanglin Luo
John E Macor
William J Pitts
Sing-Yuen Sit
Original Assignee
Bristol Myers Squibb Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Bristol Myers Squibb Co filed Critical Bristol Myers Squibb Co
Publication of SG11202102405YA publication Critical patent/SG11202102405YA/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00—Indexing scheme relating to specific properties of organic compounds
    • C07B2200/05—Isotopically modified compounds, e.g. labelled

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Rheumatology (AREA)
  • Pain & Pain Management (AREA)
  • Cardiology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Immunology (AREA)
  • Dermatology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Epidemiology (AREA)
  • Hospice & Palliative Care (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
SG11202102405YA 2018-09-13 2019-09-12 1h-indazole carboxamides as receptor-interacting protein kinase 1 inhibitors (ripk1) SG11202102405YA (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201862730602P 2018-09-13 2018-09-13
PCT/US2019/050719 WO2020056072A1 (en) 2018-09-13 2019-09-12 1h-indazole carboxamides as receptor-interacting protein kinase 1 inhibitors (ripk1)

Publications (1)

Publication Number Publication Date
SG11202102405YA true SG11202102405YA (en) 2021-04-29

Family

ID=68073171

Family Applications (1)

Application Number Title Priority Date Filing Date
SG11202102405YA SG11202102405YA (en) 2018-09-13 2019-09-12 1h-indazole carboxamides as receptor-interacting protein kinase 1 inhibitors (ripk1)

Country Status (14)

Country Link
US (1) US12172975B2 (cg-RX-API-DMAC7.html)
EP (1) EP3849968B1 (cg-RX-API-DMAC7.html)
JP (1) JP7599411B2 (cg-RX-API-DMAC7.html)
KR (1) KR102906523B1 (cg-RX-API-DMAC7.html)
CN (1) CN112673000B (cg-RX-API-DMAC7.html)
AU (1) AU2019337612A1 (cg-RX-API-DMAC7.html)
BR (1) BR112021004385A2 (cg-RX-API-DMAC7.html)
CA (1) CA3112735A1 (cg-RX-API-DMAC7.html)
EA (1) EA202190718A1 (cg-RX-API-DMAC7.html)
ES (1) ES2936481T3 (cg-RX-API-DMAC7.html)
IL (1) IL281370A (cg-RX-API-DMAC7.html)
MX (1) MX2021002509A (cg-RX-API-DMAC7.html)
SG (1) SG11202102405YA (cg-RX-API-DMAC7.html)
WO (1) WO2020056072A1 (cg-RX-API-DMAC7.html)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN111566103B (zh) 2017-10-30 2023-06-23 百时美施贵宝公司 作为激酶抑制剂的氨基咪唑并吡嗪
US11618753B2 (en) 2018-01-26 2023-04-04 Bristol-Myers Squibb Company Aminopyrrolotriazines as kinase inhibitors
KR102793119B1 (ko) 2018-09-13 2025-04-07 브리스톨-마이어스 스큅 컴퍼니 키나제 억제제로서의 인다졸 카르복스아미드
US12275721B2 (en) 2019-10-03 2025-04-15 Bristol-Myers Squibb Company Indazole carboxamides as kinase inhibitors
US11744824B2 (en) * 2020-09-15 2023-09-05 1ST Biotherapeutics, Inc. 2-amino-3-carbonyl imidazopyridine and pyrazolopyridine compounds
AR123793A1 (es) 2020-10-19 2023-01-11 Bristol Myers Squibb Co Compuestos de triazolopiridinilo como inhibidores de quinasas
WO2025106362A1 (en) * 2023-11-16 2025-05-22 Merck Sharp & Dohme Llc Ripk1 inhibitors and methods of use

Family Cites Families (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7872014B2 (en) 2003-07-23 2011-01-18 Exelixis, Inc. Anaplastic lymphoma kinase modulators and methods of use
JP2008525464A (ja) 2004-12-22 2008-07-17 メモリー・ファーマシューティカルズ・コーポレイション α−7ニコチン性受容体リガンド並びにその製造及び使用
NZ573735A (en) 2006-05-19 2011-10-28 Abbott Lab Cns active fused bicycloheterocycle substituted azabicyclic alkane derivatives
KR101061599B1 (ko) 2008-12-05 2011-09-02 한국과학기술연구원 비정상 세포 성장 질환의 치료를 위한 단백질 키나아제 저해제인 신규 인다졸 유도체, 이의 약학적으로 허용가능한염 및 이를 유효성분으로 함유하는 약학적 조성물
WO2010068287A2 (en) 2008-12-11 2010-06-17 Angion Biomedica Corp. Small molecule modulators of hepatocyte growth factor (scatter factor) activity
ES2458872T3 (es) 2009-04-30 2014-05-07 Novartis Ag Derivados de imidazol y su uso como moduladores de quinasas dependientes de ciclina
US8455516B2 (en) 2010-01-15 2013-06-04 Touro University HIV-1 fusion inhibitors and methods
KR20130077390A (ko) * 2011-12-29 2013-07-09 제이더블유중외제약 주식회사 단백질 키나아제 저해활성을 가지는 6-아미노-3-카복스아미도인다졸 유도체
EA024939B1 (ru) 2012-02-21 2016-11-30 Ацьенде Кимике Рьюните Анджелини Франческо А.К.Р.А.Ф. С.П.А. 1h-индазол-3-карбоксамидные соединения в качестве ингибиторов гликогенсинтазы киназы 3-бета
WO2013124169A1 (en) 2012-02-21 2013-08-29 Aziende Chimiche Riunite Angelini Francesco A.C.R.A.F. S.P.A. Use of 1h-indazole-3-carboxamide compounds as glycogen synthase kinase 3 beta inhibitors
US9783573B2 (en) 2012-09-18 2017-10-10 Bristol-Myers Squibb Company IAP antagonists
CN104781251B (zh) * 2012-11-08 2016-12-14 百时美施贵宝公司 可作为激酶调节剂的经双环杂环取代的吡啶基化合物
BR112016021626A2 (pt) 2014-03-20 2018-05-15 Samumed, Llc indazol-3-carboxamidas 5-substituídas e preparação e uso das mesmas
US10933068B2 (en) 2016-05-26 2021-03-02 Sonic Master Limited Modulators of DUX4 for regulation of muscle function
LT3580220T (lt) 2017-02-13 2021-12-27 Bristol-Myers Squibb Company Aminotriazolopiridinai, kaip kinazės inhibitoriai
CN111566103B (zh) 2017-10-30 2023-06-23 百时美施贵宝公司 作为激酶抑制剂的氨基咪唑并吡嗪
US11618753B2 (en) 2018-01-26 2023-04-04 Bristol-Myers Squibb Company Aminopyrrolotriazines as kinase inhibitors
KR102793119B1 (ko) 2018-09-13 2025-04-07 브리스톨-마이어스 스큅 컴퍼니 키나제 억제제로서의 인다졸 카르복스아미드
US12275721B2 (en) 2019-10-03 2025-04-15 Bristol-Myers Squibb Company Indazole carboxamides as kinase inhibitors

Also Published As

Publication number Publication date
KR102906523B1 (ko) 2025-12-30
BR112021004385A2 (pt) 2021-07-20
CN112673000B (zh) 2024-10-18
ES2936481T3 (es) 2023-03-17
MX2021002509A (es) 2021-04-28
JP7599411B2 (ja) 2024-12-13
WO2020056072A1 (en) 2020-03-19
JP2022500418A (ja) 2022-01-04
CA3112735A1 (en) 2020-03-19
EP3849968A1 (en) 2021-07-21
CN112673000A (zh) 2021-04-16
KR20210060517A (ko) 2021-05-26
US20220380335A1 (en) 2022-12-01
IL281370A (en) 2021-04-29
EP3849968B1 (en) 2022-12-21
US12172975B2 (en) 2024-12-24
EA202190718A1 (ru) 2021-07-01
AU2019337612A1 (en) 2021-05-13

Similar Documents

Publication Publication Date Title
IL287136B1 (en) Receptor inhibitors - interacting with protein kinase 1
IL281370A (en) 1h-indazole carboxamides as receptor-interacting protein kinase 1 inhibitors (ripk1)
IL282179A (en) Protein tyrosine phosphatase inhibitors
DK3788042T3 (en) Bcl 2 inhibitorer
IL280719A (en) Transglutaminase 2 (tg2) inhibitors
ZA202006581B (en) Phenyl triazole mll1-wdr5 protein-protein interaction inhibitor
IL281371A (en) Indazole carboxamides as kinase inhibitors
SI3397631T1 (sl) Substituirani 3-azabiciklo(3.1.0)heksani kot zaviralci ketoheksokinaze
PL3317269T3 (pl) Laktamy bicykliczne jako inhibitory kinazy białka oddziałującego z receptorem-1 (rip1) do leczenia np. chorób zapalnych
IL281146A (en) Dimethyl amino aztidine amides as JAK inhibitors
GB202015103D0 (en) Data anonymization
ZA202000107B (en) Aminothiazole compounds as protein kinase inhibitors
PL3735778T4 (pl) Współrzędne jako dane pomocnicze
GB201807845D0 (en) Kinase Inhibitors
EP3476848A4 (en) BENZOFURANE-PYRAZOLE-AMINE PROTEIN KINASE INHIBITOR
EP3258926A4 (en) Dimethoxyphenyl inhibitors of vesicular monoamine transporter 2
IL279215A (en) Mitogen-activated protein kinase kinase 7 inhibitors
GB202103599D0 (en) Enabling software distribution
EP3687353B8 (en) High limit rtd holder block
GB201819391D0 (en) Media supply units
GB201810016D0 (en) Microbial hosts for protein production
PH32019001382S1 (en) Vase (2)
PH32019001383S1 (en) Vase (3)
PH32019001386S1 (en) Vase (4)
HK40000109A (en) Inhibitors of receptor-interacting protein kinase 1